203 related articles for article (PubMed ID: 30714241)
21. Comparison of
Doré V; Bullich S; Rowe CC; Bourgeat P; Konate S; Sabri O; Stephens AW; Barthel H; Fripp J; Masters CL; Dinkelborg L; Salvado O; Villemagne VL; De Santi S
Alzheimers Dement; 2019 Jun; 15(6):807-816. PubMed ID: 31101517
[TBL] [Abstract][Full Text] [Related]
22. A new integrated dual time-point amyloid PET/MRI data analysis method.
Cecchin D; Barthel H; Poggiali D; Cagnin A; Tiepolt S; Zucchetta P; Turco P; Gallo P; Frigo AC; Sabri O; Bui F
Eur J Nucl Med Mol Imaging; 2017 Nov; 44(12):2060-2072. PubMed ID: 28674847
[TBL] [Abstract][Full Text] [Related]
23. Coupled Imaging with [
Chiaravalloti A; Castellano AE; Ricci M; Barbagallo G; Sannino P; Ursini F; Karalis G; Schillaci O
Mol Imaging Biol; 2018 Aug; 20(4):659-666. PubMed ID: 29404839
[TBL] [Abstract][Full Text] [Related]
24. Imaging of amyloid beta in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism.
Rowe CC; Ackerman U; Browne W; Mulligan R; Pike KL; O'Keefe G; Tochon-Danguy H; Chan G; Berlangieri SU; Jones G; Dickinson-Rowe KL; Kung HP; Zhang W; Kung MP; Skovronsky D; Dyrks T; Holl G; Krause S; Friebe M; Lehman L; Lindemann S; Dinkelborg LM; Masters CL; Villemagne VL
Lancet Neurol; 2008 Feb; 7(2):129-35. PubMed ID: 18191617
[TBL] [Abstract][Full Text] [Related]
25. Comparison of qualitative and quantitative imaging characteristics of [11C]PiB and [18F]flutemetamol in normal control and Alzheimer's subjects.
Mountz JM; Laymon CM; Cohen AD; Zhang Z; Price JC; Boudhar S; McDade E; Aizenstein HJ; Klunk WE; Mathis CA
Neuroimage Clin; 2015; 9():592-8. PubMed ID: 26640770
[TBL] [Abstract][Full Text] [Related]
26. Aβ imaging with 18F-florbetaben in prodromal Alzheimer's disease: a prospective outcome study.
Ong KT; Villemagne VL; Bahar-Fuchs A; Lamb F; Langdon N; Catafau AM; Stephens AW; Seibyl J; Dinkelborg LM; Reininger CB; Putz B; Rohde B; Masters CL; Rowe CC
J Neurol Neurosurg Psychiatry; 2015 Apr; 86(4):431-6. PubMed ID: 24970906
[TBL] [Abstract][Full Text] [Related]
27. Cross-sectional comparison of small animal [18F]-florbetaben amyloid-PET between transgenic AD mouse models.
Brendel M; Jaworska A; Grießinger E; Rötzer C; Burgold S; Gildehaus FJ; Carlsen J; Cumming P; Baumann K; Haass C; Steiner H; Bartenstein P; Herms J; Rominger A
PLoS One; 2015; 10(2):e0116678. PubMed ID: 25706990
[TBL] [Abstract][Full Text] [Related]
28. PETPVE12: an SPM toolbox for Partial Volume Effects correction in brain PET - Application to amyloid imaging with AV45-PET.
Gonzalez-Escamilla G; Lange C; Teipel S; Buchert R; Grothe MJ;
Neuroimage; 2017 Feb; 147():669-677. PubMed ID: 28039094
[TBL] [Abstract][Full Text] [Related]
29. The Incremental Diagnostic Value of [18F]Florbetaben PET and the Pivotal Role of the Neuropsychological Assessment in Clinical Practice.
Spallazzi M; Barocco F; Michelini G; Morelli N; Scarlattei M; Baldari G; Ruffini L; Caffarra P
J Alzheimers Dis; 2019; 67(4):1235-1244. PubMed ID: 30689568
[TBL] [Abstract][Full Text] [Related]
30. Cerebral amyloid-β PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study.
Barthel H; Gertz HJ; Dresel S; Peters O; Bartenstein P; Buerger K; Hiemeyer F; Wittemer-Rump SM; Seibyl J; Reininger C; Sabri O;
Lancet Neurol; 2011 May; 10(5):424-35. PubMed ID: 21481640
[TBL] [Abstract][Full Text] [Related]
31. Amyloid-β Deposition and Long-Term Progression in Mild Cognitive Impairment due to Alzheimer's Disease Defined with Amyloid PET Imaging.
Hatashita S; Wakebe D
J Alzheimers Dis; 2017; 57(3):765-773. PubMed ID: 28304292
[TBL] [Abstract][Full Text] [Related]
32. Optimal Reference Region to Measure Longitudinal Amyloid-β Change with
Bullich S; Villemagne VL; Catafau AM; Jovalekic A; Koglin N; Rowe CC; De Santi S
J Nucl Med; 2017 Aug; 58(8):1300-1306. PubMed ID: 28183994
[TBL] [Abstract][Full Text] [Related]
33. [Amyloid positron-emission-tomography with [
Schönecker S; Prix C; Raiser T; Ackl N; Wlasich E; Stenglein-Krapf G; Mille E; Brendel M; Sabri O; Patt M; Barthel H; Bartenstein P; Levin J; Rominger A; Danek A
Nervenarzt; 2017 Feb; 88(2):156-161. PubMed ID: 27913818
[TBL] [Abstract][Full Text] [Related]
34. Florbetaben to trace amyloid-β in the Alzheimer brain by means of PET.
Barthel H; Sabri O
J Alzheimers Dis; 2011; 26 Suppl 3():117-21. PubMed ID: 21971456
[TBL] [Abstract][Full Text] [Related]
35. Low-dose CT for the spatial normalization of PET images: A validation procedure for amyloid-PET semi-quantification.
Presotto L; Iaccarino L; Sala A; Vanoli EG; Muscio C; Nigri A; Bruzzone MG; Tagliavini F; Gianolli L; Perani D; Bettinardi V
Neuroimage Clin; 2018; 20():153-160. PubMed ID: 30094164
[TBL] [Abstract][Full Text] [Related]
36. Assessment of change in glucose metabolism in white matter of amyloid-positive patients with Alzheimer disease using F-18 FDG PET.
Jeong YJ; Yoon HJ; Kang DY
Medicine (Baltimore); 2017 Dec; 96(48):e9042. PubMed ID: 29310421
[TBL] [Abstract][Full Text] [Related]
37. PET quantification of 18F-florbetaben binding to β-amyloid deposits in human brains.
Becker GA; Ichise M; Barthel H; Luthardt J; Patt M; Seese A; Schultze-Mosgau M; Rohde B; Gertz HJ; Reininger C; Sabri O
J Nucl Med; 2013 May; 54(5):723-31. PubMed ID: 23471310
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of Tau Imaging in Staging Alzheimer Disease and Revealing Interactions Between β-Amyloid and Tauopathy.
Wang L; Benzinger TL; Su Y; Christensen J; Friedrichsen K; Aldea P; McConathy J; Cairns NJ; Fagan AM; Morris JC; Ances BM
JAMA Neurol; 2016 Sep; 73(9):1070-7. PubMed ID: 27454922
[TBL] [Abstract][Full Text] [Related]
39. A Cross-Validation of FDG- and Amyloid-PET Biomarkers in Mild Cognitive Impairment for the Risk Prediction to Dementia due to Alzheimer's Disease in a Clinical Setting.
Iaccarino L; Chiotis K; Alongi P; Almkvist O; Wall A; Cerami C; Bettinardi V; Gianolli L; Nordberg A; Perani D
J Alzheimers Dis; 2017; 59(2):603-614. PubMed ID: 28671117
[TBL] [Abstract][Full Text] [Related]
40. Imaging of amyloid plaques and cerebral glucose metabolism in semantic dementia and Alzheimer's disease.
Drzezga A; Grimmer T; Henriksen G; Stangier I; Perneczky R; Diehl-Schmid J; Mathis CA; Klunk WE; Price J; DeKosky S; Wester HJ; Schwaiger M; Kurz A
Neuroimage; 2008 Jan; 39(2):619-33. PubMed ID: 17962045
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
